Navigation Links
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Date:6/1/2009

ur weeks, respectively, achieved clinical remission as measured by the CDAI.

No new or unexpected safety signals were observed in this study. Adverse events were previously reported from the WELCOME study: the most common adverse events were headache, nasopharyngitis and nausea. The incidence of serious adverse events (SAEs) was seven percent and the most frequent SAEs involved gastrointestinal disorders (five percent) and infections and infestations (2 percent).

Additional data from the WELCOME study presented at DDW, includes:

  • Health-related Quality of Life: Cimzia(R) (400 mg) administered at every two or four weeks similarly improved patient-reported health-related quality of life as measured by the Inflammatory Bowel Disease Questionnaire (a validated tool assessing bowel symptoms, systematic symptoms, emotional function and social function) by Week 26. (Abstract #S1058)
  • Efficacy Independent of IFX Dosing: Cimzia(R) (400 mg) was efficacious in rapidly inducing a clinical response in the infliximab-refractory patient population regardless of the previous dosages of infliximab. (Abstract #S1064)

"As we continue to study Cimzia(R)'s potential efficacy, we are pleased to be adding to an impressive body of data that supports the use of Cimzia(R) for a variety of moderate to severe Crohn's disease patients," said David Robinson, vice president and general manager of UCB's Immunology Business Unit.

Recently, UCB announced that Cimzia(R) is now available to Crohn's patients in a pre-filled syringe, developed in partnership with OXO Good Grips(R) for subcutaneous self-administration once every four weeks after initial dosing. Cimzia(R), manufactured by UCB, was approved by the U.S. Food and Drug Administration on April 22, 2008.

About WELCOME

The WELCOME study is a 539 pa
'/>"/>

SOURCE UCB, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
2. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Resverlogix Provides Quarterly Update
7. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
8. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
9. US Oncology Provides Full Service Management of Clinical Trials
10. SemBioSys provides update on insulin program
11. Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , Apr. 1, 2015 Goldman Small ... the small cap and microcap sectors, announced today that ... Inc. (OTCQB – PMCB), a publicly traded clinical stage ... cancer and diabetes. To view the sponsored research article, ... in its entirety, please visit www.GoldmanResearch.com .  ...
(Date:4/1/2015)... , April 1, 2015  Among 1,050 U.S. consumers, ... oral cancer (68 percent) and only 36 percent reported ... check-up, according to findings from a survey ... leading innovator and developer of solutions that aid in ... The online survey polled 1,050 U.S. consumers on their ...
(Date:4/1/2015)... ROCKVILLE, Md. , April 1, 2015 /PRNewswire/ ... developer of pathogen-specific therapies for serious infections and ... today announced that clinical data supporting the development ... degrade certain beta-lactam intravenous (IV) antibiotics within the ... of the gut microbiome for the prevention of ...
(Date:4/1/2015)... 2015 Earlier this year, A.J. ... sciences industry association that represents research-based life science organizations ... Jonathan Parker, AJO’s Vice President of Business Development & ... an event that attracted over 750 attendees. , ... 73 year old cancer survivor shared his moving story ...
Breaking Biology Technology:Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... the Company,s request for an,extension until December 3, ... market capitalization requirement of $35 million or the ... order to remain,listed. There can be no assurance ...
... Aortic ... Aneurysms, ... of Vascular Surgery was the first to implant, in,Phoenix, the Powerlink ... aortic aneurysms (AAA). The procedure was,performed at Arizona Heart Hospital by ...
... BOSTON, Oct. 31 PAREXEL International,Corporation (Nasdaq: ... at the,Oppenheimer 19th Annual Healthcare Conference in New ... Financial Officer will be making,a formal presentation on ... 3,2008., The presentation will be available under ...
Cached Biology Technology:Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 3PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference 2
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... 2012 Childhood Obesity , a peer-reviewed journal from Mary ... dedicated to the role that schools can and should ... eating habits to help stem the tide of the ... provides comprehensive coverage of food policy, systems, and programs ...
... becomes extinct, other predatory species could soon follow, according to ... a University of Exeter team has now carried out the ... 2012) in the Royal Society journal Biology Letters , ... can indirectly cause another to become extinct. The University of ...
... Biofuels and Texas AgriLife Research, part of The Texas ... develop and commercialize cellulosic feedstocks for the production of ... diverse high biomass energy crop breeding program and BP ... companies growing commercial-scale biomass crops for liquid fuels. ...
Cached Biology News:School food -- on the front line in the fight against childhood obesity 2Study proves that 1 extinction leads to another 2BP Biofuels, Texas AgriLife Research sign agreement to advance biofuel feedstock development 2
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... The PRO S-7 stirrers ... Spill-resistant housing channels fluids away ... panel features easy-to-use controls which ... 7"x7" ceramic tops feature ...
... loxP-cm-loxP cassette is designed to ... The prokaryotic promoter gb2 driving ... a slightly modified version of the ... efficiency than the generally used Tn5 ...
... This kit is designed for the ... large vector plasmids at any position (for ... included loxP-PGK-gb2-neo-loxP cassette is designed to allow ... eukaryotic cells. It combines a prokaryotic promoter ...
Biology Products: